TRAVERE THERAPEUTICS, INC. Weighted Average Number of Shares Outstanding, Basic and Diluted
TRAVERE THERAPEUTICS, INC. (TVTX) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 47.54 million shares for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2021-03-01
- TRAVERE THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-12-31 was 51.29M shares, a 19.20% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-09-30 was 50.93M shares, a 18.60% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-06-30 was 44.76M shares, a 6.69% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2019-12-31 was 43.03M shares, a 4.23% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 47.54M shares, a 12.28% increase from fiscal 2019.
- TRAVERE THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 42.34M shares, a 4.72% increase from fiscal 2018.
- TRAVERE THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2018 was 40.43M shares, a 4.29% increase from fiscal 2017.
- TRAVERE THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2017 was 38.77M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 10 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|---|
| 2020-12-31 | 51.29M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | 51.11M shares derived: average of 2 quarters · filed 2021-03-01 | 48.99M shares derived: average of 3 quarters · filed 2021-03-01 | 47.54M shares 10-K · filed 2021-03-01 | |
| 2020-09-30 | 50.93M shares 10-Q · filed 2020-11-05 | 47.85M shares derived: average of 2 quarters · filed 2020-11-05 | 46.29M shares 10-Q · filed 2020-11-05 | ||
| 2020-06-30 | 44.76M shares 10-Q · filed 2020-07-31 | 43.94M shares 10-Q · filed 2020-07-31 | |||
| 2019-12-31 | 43.03M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | 42.99M shares derived: average of 2 quarters · filed 2021-03-01 | 42.64M shares derived: average of 3 quarters · filed 2021-03-01 | 42.34M shares 10-K · filed 2021-03-01 | |
| 2019-09-30 | 42.94M shares 10-Q · filed 2020-11-05 | 42.45M shares derived: average of 2 quarters · filed 2020-11-05 | 42.11M shares 10-Q · filed 2020-11-05 | 41.90M shares derived: average of 4 quarters · filed 2021-03-01 | |
| 2019-06-30 | 41.96M shares 10-Q · filed 2020-07-31 | 41.69M shares 10-Q · filed 2020-07-31 | 41.55M shares derived: average of 3 quarters · filed 2021-03-01 | 41.34M shares derived: average of 4 quarters · filed 2021-03-01 | |
| 2019-03-31 | 41.41M shares 10-Q · filed 2019-05-07 | 41.35M shares derived: average of 2 quarters · filed 2021-03-01 | 41.14M shares derived: average of 3 quarters · filed 2021-03-01 | 40.87M shares derived: average of 4 quarters · filed 2021-03-01 | |
| 2018-12-31 | 41.29M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | 41.00M shares derived: average of 2 quarters · filed 2021-03-01 | 40.69M shares derived: average of 3 quarters · filed 2021-03-01 | 40.43M shares 10-K · filed 2021-03-01 | |
| 2018-09-30 | 40.72M shares 10-Q · filed 2019-10-30 | 40.39M shares derived: average of 2 quarters · filed 2019-10-30 | 40.15M shares 10-Q · filed 2019-10-30 | 40.15M shares derived: average of 4 quarters · filed 2020-02-24 | |
| 2018-06-30 | 40.06M shares 10-Q · filed 2019-08-06 | 39.64M shares 10-Q · filed 2019-08-06 | 39.96M shares derived: average of 3 quarters · filed 2020-02-24 | 39.64M shares derived: average of 4 quarters · filed 2020-02-24 | |
| 2018-03-31 | 39.66M shares 10-Q · filed 2019-05-07 | 39.92M shares derived: average of 2 quarters · filed 2020-02-24 | 39.50M shares derived: average of 3 quarters · filed 2020-02-24 | 39.38M shares derived: average of 4 quarters · filed 2020-02-24 | |
| 2017-12-31 | 40.17M shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | 39.41M shares derived: average of 2 quarters · filed 2020-02-24 | 39.29M shares derived: average of 3 quarters · filed 2020-02-24 | 38.77M shares 10-K · filed 2020-02-24 | |
| 2017-09-30 | 38.65M shares 10-Q · filed 2018-11-01 | 38.85M shares derived: average of 2 quarters · filed 2018-11-01 | 38.30M shares 10-Q · filed 2018-11-01 | ||
| 2017-06-30 | 39.04M shares 10-Q · filed 2018-08-03 | 38.55M shares 10-Q · filed 2018-08-03 | |||
| 2014-12-31 | 25.06M shares 10-K · filed 2015-03-11 | ||||
| 2014-03-31 | 23.33M shares 10-Q · filed 2014-05-15 | 20.88M shares derived: average of 2 quarters · filed 2015-07-09 | 19.04M shares derived: average of 3 quarters · filed 2015-07-09 | 17.35M shares derived: average of 4 quarters · filed 2015-07-09 | |
| 2013-12-31 | 18.43M shares derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2015-07-09 | 16.90M shares derived: average of 2 quarters · filed 2015-07-09 | 15.35M shares derived: average of 3 quarters · filed 2015-07-09 | 14.21M shares 10-K/A · filed 2015-07-09 | |
| 2013-09-30 | 15.37M shares 10-Q/A · filed 2015-07-09 | 13.81M shares derived: average of 2 quarters · filed 2015-07-09 | 12.80M shares 10-Q/A · filed 2015-07-09 | 10.97M shares derived: average of 4 quarters · filed 2015-07-09 | |
| 2013-06-30 | 12.25M shares 10-Q · filed 2013-09-16 | 11.49M shares 10-Q · filed 2013-09-16 | 9.51M shares derived: average of 3 quarters · filed 2015-07-09 | ||
| 2013-03-31 | 10.70M shares 10-Q · filed 2014-05-15 | 8.13M shares derived: average of 2 quarters · filed 2015-07-09 | |||
| 2012-12-31 | 5.57M shares derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2015-07-09 | 3.66M shares 10-K/A · filed 2015-07-09 | |||
| 2012-11-30 | 106.69K shares 10-Q · filed 2013-03-06 | 106.69K shares 10-Q · filed 2013-03-06 | |||
| 2012-09-30 | 3.51M shares 10-Q/A · filed 2015-07-09 | 3.03M shares 10-Q/A · filed 2015-07-09 | |||
| 2012-08-31 | 106.69K shares 10-Q · filed 2012-10-10 | 106.69K shares 10-Q · filed 2012-10-10 | |||
| 2012-06-30 | 3.06M shares 10-Q · filed 2013-09-16 | 2.78M shares 10-Q · filed 2013-09-16 | |||
| 2012-05-31 | 106.69K shares 10-Q · filed 2012-08-08 | ||||
| 2012-03-31 | 2.50M shares 10-Q/A · filed 2013-09-16 | ||||
| 2012-02-29 | 106.68K shares 10-K · filed 2012-05-24 | ||||
| 2011-12-31 | 2.05M shares 10-K/A · filed 2013-09-16 | ||||
| 2011-11-30 | 106.69K shares 10-Q · filed 2013-03-06 | 106.69K shares derived: average of 2 quarters · filed 2013-03-06 | 106.69K shares 10-Q · filed 2013-03-06 | ||
| 2011-08-31 | 106.69K shares 10-Q · filed 2012-10-10 | 106.69K shares 10-Q · filed 2012-10-10 | |||
| 2011-05-31 | 106.69K shares 10-Q · filed 2012-08-08 | ||||
| 2011-02-28 | 106.68K shares 10-K · filed 2012-05-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |